NAFLD1
MCID: FTT008
MIFTS: 58

Fatty Liver Disease, Nonalcoholic 1 (NAFLD1)

Categories: Cancer diseases, Liver diseases, Metabolic diseases

Aliases & Classifications for Fatty Liver Disease, Nonalcoholic 1

MalaCards integrated aliases for Fatty Liver Disease, Nonalcoholic 1:

Name: Fatty Liver Disease, Nonalcoholic 1 57 29 6
Hepatic Steatosis 74 29 6
Fatty Liver Disease, Nonalcoholic, Susceptibility to, 1 57 13
Nafld1 57 74
Non-Alcoholic Fatty Liver Disease 1 74
Steatohepatitis 72
Fatty Liver 72

Characteristics:

OMIM:

57
Inheritance:
multifactorial

Miscellaneous:
genetic heterogeneity


HPO:

32
fatty liver disease, nonalcoholic 1:
Inheritance heterogeneous


Classifications:



External Ids:

OMIM 57 613282
MeSH 44 D005234
UMLS 72 C0015695 C2711227

Summaries for Fatty Liver Disease, Nonalcoholic 1

OMIM : 57 The accumulation of excess triglyceride in the liver, a condition known as hepatic steatosis (or fatty liver), is associated with adverse metabolic consequences including insulin resistance and dyslipidemia. Factors promoting deposition of fat in the liver include obesity, diabetes, insulin resistance, and alcohol ingestion. Nonalcoholic fatty liver disease (NAFLD) is the most common form of liver disease in Western countries. In a subset of individuals hepatic steatosis promotes an inflammatory response in the liver, referred to as steatohepatitis, which can progress to cirrhosis and liver cancer (summary by Romeo et al., 2008). Cohen et al. (2011) reviewed nonalcoholic fatty liver disease. (613282)

MalaCards based summary : Fatty Liver Disease, Nonalcoholic 1, also known as hepatic steatosis, is related to lipodystrophy, familial partial, type 2 and chylomicron retention disease. An important gene associated with Fatty Liver Disease, Nonalcoholic 1 is PRMT7 (Protein Arginine Methyltransferase 7), and among its related pathways/superpathways are Metabolism and Common Cytokine Receptor Gamma-Chain Family Signaling Pathways. The drugs Entecavir and Telmisartan have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and adipocyte, and related phenotypes are hepatic steatosis and homeostasis/metabolism

UniProtKB/Swiss-Prot : 74 Non-alcoholic fatty liver disease 1: A condition characterized by accumulation of triglycerides in the liver. It is associated with adverse metabolic consequences, including insulin resistance and dyslipidemia. In a subset of individuals, hepatic steatosis promotes an inflammatory response in the liver, referred to as steatohepatitis, which can progress to cirrhosis and liver cancer. NAFLD is the most common form of liver disease in Western countries.

Related Diseases for Fatty Liver Disease, Nonalcoholic 1

Diseases in the Fatty Liver Disease, Nonalcoholic 1 family:

Fatty Liver Disease, Nonalcoholic 2

Diseases related to Fatty Liver Disease, Nonalcoholic 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 303)
# Related Disease Score Top Affiliating Genes
1 lipodystrophy, familial partial, type 2 33.0 LEP INS
2 chylomicron retention disease 31.9 MTTP FABP1
3 lipodystrophy, congenital generalized, type 1 31.8 LEP INS ADIPOQ
4 kwashiorkor 30.8 SLC17A5 GPT
5 atherosclerosis susceptibility 30.8 PPARA INS ADIPOQ
6 hyperglycemia 30.8 LEP INS ADIPOQ
7 acquired generalized lipodystrophy 30.6 RETN LEP INS ADIPOQ
8 fatty liver disease 30.6 SREBF1 SLC17A5 PPARA PNPLA3 LEP INS
9 familial hyperlipidemia 30.3 PRMT7 PPARA INS
10 mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome 30.3 INS ADIPOQ
11 glucose intolerance 29.8 RETN LEP INS ADIPOQ
12 fetal macrosomia 29.7 LEP INS
13 prediabetes syndrome 29.6 LEP INS ADIPOQ
14 apnea, obstructive sleep 29.6 LEP INS ADIPOQ
15 sleep apnea 29.6 LEP INS ADIPOQ
16 arteries, anomalies of 29.5 LEP INS ADIPOQ
17 acute liver failure 29.5 SLC17A5 GPT
18 liver disease 29.5 SLC17A5 PPARA PNPLA3 LEP INS GPT
19 acanthosis nigricans 29.5 PRMT7 LEP INS ADIPOQ
20 lipid storage disease 29.4 SREBF1 PNPLA3 INS ADIPOQ
21 proteasome-associated autoinflammatory syndrome 1 29.3 RETN PPARA INS ADIPOQ
22 coronary heart disease 1 29.2 RETN INS ADIPOQ
23 liver cirrhosis 29.1 SLC17A5 RETN LEP GPT ADIPOQ
24 gestational diabetes 28.7 RETN LEP INS ADIPOQ
25 lipid metabolism disorder 28.7 RETN PPARA MTTP LEP INS ADIPOQ
26 diabetes mellitus 28.5 RETN PPARA LEP INS ADIPOQ
27 hypertension, essential 28.4 RETN LEP INS ADIPOQ
28 overnutrition 27.5 SREBF1 RETN PPARA LEP INS ADIPOQ
29 body mass index quantitative trait locus 11 26.2 SREBF1 RETN PRMT7 PPARA PNPLA3 MTTP
30 diabetes mellitus, noninsulin-dependent 25.9 SREBF1 SLC17A5 RETN PRMT7 PPARA MTTP
31 lipoatrophy with diabetes, hepatic steatosis, cardiomyopathy, and leukomelanodermic papules 12.4
32 hypobetalipoproteinemia, familial, 1 11.6
33 congenital generalized lipodystrophy 11.6
34 abetalipoproteinemia 11.6
35 citrullinemia, type ii, adult-onset 11.6
36 familial partial lipodystrophy 11.6
37 lipodystrophy, congenital generalized, type 2 11.4
38 3-methylglutaconic aciduria, type v 11.4
39 lipodystrophy, congenital generalized, type 3 11.4
40 lipodystrophy, familial partial, type 6 11.4
41 visceral steatosis 11.4
42 lipoatrophy with diabetes, leukomelanodermic papules, liver steatosis, and hypertrophic cardiomyopathy 11.4
43 adrenomyodystrophy 11.3
44 mitochondrial trifunctional protein deficiency 11.3
45 neutral lipid storage disease with myopathy 11.3
46 lipodystrophy, congenital generalized, type 4 11.3
47 lipodystrophy, familial partial, type 5 11.3
48 muscular dystrophy, limb-girdle, autosomal recessive 18 11.3
49 combined oxidative phosphorylation deficiency 16 11.3
50 combined oxidative phosphorylation deficiency 21 11.3

Graphical network of the top 20 diseases related to Fatty Liver Disease, Nonalcoholic 1:



Diseases related to Fatty Liver Disease, Nonalcoholic 1

Symptoms & Phenotypes for Fatty Liver Disease, Nonalcoholic 1

Human phenotypes related to Fatty Liver Disease, Nonalcoholic 1:

32
# Description HPO Frequency HPO Source Accession
1 hepatic steatosis 32 HP:0001397

Symptoms via clinical synopsis from OMIM:

57
Abdomen Liver:
fatty liver (hepatic steatosis), nonalcoholic

Clinical features from OMIM:

613282

MGI Mouse Phenotypes related to Fatty Liver Disease, Nonalcoholic 1:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.73 ADIPOQ FABP1 HADHA INS LEP MTTP
2 adipose tissue MP:0005375 9.63 ADIPOQ INS LEP PNPLA3 PPARA RETN
3 liver/biliary system MP:0005370 9.36 ADIPOQ FABP1 HADHA INS LEP MTTP

Drugs & Therapeutics for Fatty Liver Disease, Nonalcoholic 1

Drugs for Fatty Liver Disease, Nonalcoholic 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 468)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
2
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
3
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
4
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
5
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
6
Ribavirin Approved Phase 4 36791-04-5 37542
7
Metformin Approved Phase 4 657-24-9 4091 14219
8
Tocopherol Approved, Investigational Phase 4 1406-66-2, 54-28-4 14986
9
Insulin Detemir Approved Phase 4 169148-63-4 5311023
10
Insulin Aspart Approved Phase 4 116094-23-6 16132418
11
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
12
Liraglutide Approved Phase 4 204656-20-2 44147092
13
Glucagon Approved Phase 4 16941-32-5
14
Rifampicin Approved Phase 4 13292-46-1 5381226 5458213
15
Propranolol Approved, Investigational Phase 4 525-66-6 4946
16
Gliclazide Approved Phase 4 21187-98-4 3475
17
Glipizide Approved, Investigational Phase 4 29094-61-9 3478
18
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
19
Zidovudine Approved Phase 4 30516-87-1 35370
20
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
21
Tamoxifen Approved Phase 4 10540-29-1 2733526
22
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
23
Ergotamine Approved Phase 4 113-15-5 8223
24
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
25
Nortriptyline Approved Phase 4 72-69-5 4543
26
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
27
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
28
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
29
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 23925 27284
30
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
31
Glimepiride Approved Phase 4 93479-97-1 3476
32
Phentermine Approved, Illicit Phase 4 122-09-8 4771
33
Sorafenib Approved, Investigational Phase 4 284461-73-0 216239 406563
34
tannic acid Approved Phase 4 1401-55-4
35
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
36
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
37
Dulaglutide Approved, Investigational Phase 4 923950-08-7
38
Alogliptin Approved Phase 4 850649-61-5 11450633
39
Empagliflozin Approved Phase 4 864070-44-0
40
Testosterone enanthate Approved Phase 4 315-37-7 9416
41
Methyltestosterone Approved Phase 4 58-18-4 6010
42
Testosterone Approved, Experimental, Investigational Phase 4 481-30-1, 58-22-0 6013 10204
43
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
44
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
45
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
46
Zinc Approved, Investigational Phase 4 7440-66-6 32051
47
Insulin glargine Approved Phase 4 160337-95-1
48
Rifaximin Approved, Investigational Phase 4 80621-81-4 46783403 6436173
49
Saxagliptin Approved Phase 4 361442-04-8 11243969
50
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793

Interventional clinical trials:

(show top 50) (show all 1140)
# Name Status NCT ID Phase Drugs
1 Complex Imaging Assessment of Steatosis in Patients Under Treatment With Combination Silimarin, Phyllanthus Niruri and Choline Unknown status NCT02669641 Phase 4
2 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients-A Randomized, Double-Blinded, Controlled Trial Unknown status NCT01148576 Phase 4 entecavir;entecavir;essentiale + entecavir;Vitamin E + entecavir
3 Ultrasonographic Modification of Liver Steatosis and Visceral Fat Induced by Treatment With Losartan and Simvastatin in Hypertensive Normocholesterolemic Obese Patients Unknown status NCT00669435 Phase 4 Losartan + Simvastatin;Amlodipine + Simvastatin
4 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
5 A Randomised Controlled Trial of Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
6 Endobarrier Treatment in Obese Subjects With T2DM Unknown status NCT01718457 Phase 4
7 The Effect of Empagliflozin on NAFLD in Asian Patients With Type 2 Diabetes Unknown status NCT02964715 Phase 4 Empagliflozin
8 Randomized Study Comparing Switching to Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Monoinfected Patients Impact on Fatty Liver and Liver Fibrosis Assessed by Noninvasive Diagnostic Methods Unknown status NCT02210715 Phase 4 Isentress.
9 THE EFFECT OF DUAL TREATMENT WITH L-CARNITINE AND MAGNESIUM ON Patients With Non Alcoholic Fatty Liver Disease Unknown status NCT01956825 Phase 4
10 An Randomized Open Label Trial on the Impact of 24 Weeks of Atorvastatin Therapy on Liver Fat Content and Abdominal Fat Content in Patients With Type 2 Diabetes Combined With High LDL-C and Non-alcoholic Fatty Liver Disease Unknown status NCT01720719 Phase 4 atorvastatin;Vitamin E
11 The Effect of Obesity in Dexmedetomidine Metabolic Clearance Unknown status NCT02557867 Phase 4 Dexmedetomidine
12 Evaluation of Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial Unknown status NCT02213224 Phase 4 Perindopril;Telmisartan;Amlodipine
13 Double Blinded Randomised Trial Comparing Metformin Versus Placebo in NASH Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4 Metformin
14 Effect of Liraglutide on Fatty Liver Content Evaluated by Proton-spectroscopy (1H-spectroscopy) and Lipoprotein Kinetic, in Patients With Type 2 Diabetes Unknown status NCT02721888 Phase 4 Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
15 Exenatide BID Compared With Insulin Glargine to Change Liver Fat Content in Non-alcoholic Fatty-liver Disease Patients With Type 2 Diabetes Unknown status NCT02303730 Phase 4 Exenatide;insulin glargine
16 Personalized Medicine in HCV Chronic Infection. Endothelial Dysfunction and Subclinical Atheromatosis in Patients With HCV Infection. Characterization and Potential Reversibility With Direct Antiviral Agents. Unknown status NCT02802280 Phase 4
17 A Multi-Centered, Prospective, Randomized, Placebo-Controlled Clinical Trial for the Treatment of Significant Steatosis or NASH With Xenical Followed by Treatment of Hepatitis C (HCV) With PEG-Interferon Alpha-2a/Copegus Completed NCT00207311 Phase 4 Xenical, Pegasys, Copegus
18 Effects of Exenatide (Byetta®) on Biochemical and Histological Parameters of Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT01208649 Phase 4 Exenatide
19 A New Treatment Strategy of Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD) Completed NCT01006889 Phase 4 Exenatide
20 Biochemical and Echosonographic Impacts Using Siliphos-Selenium-Methionine-Alpha Lipoic Acid + Metformin Versus Metformin in Patients With Fatty Liver and Steatohepatitis Completed NCT01650181 Phase 4 Metformin;Metformin
21 Pioglitazone in Hepatitis C: A Randomized, Double Blind, Placebo-controlled Study Completed NCT00189163 Phase 4 Pioglitazone;Placebo Oral Tablet
22 Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone Completed NCT02875821 Phase 4 Ipragliflozin;metformin with pioglitazone
23 Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) to Improve Insulin Secretion and Action in Subjects With Type 2 Diabetes Completed NCT00998335 Phase 4 Long-acting bedtime insulin detemir (Levemir);Insulin detemir and pre-meal insulin aspart.
24 Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT00160407 Phase 4 Orlistat (Xenical)
25 Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among HIV/HCV-Coinfected Patients Receiving Two Nucleoside Analogs Plus Efavirenz: The Steral Study Completed NCT01900015 Phase 4 Raltegravir;Efavirenz
26 Long-term Role of Pioglitazone in Non-Alcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes Mellitus (T2DM). Completed NCT00994682 Phase 4 Pioglitazone study drug;Placebo;Pioglitazone Open Label
27 Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) Completed NCT00227110 Phase 4 Pioglitazone;Placebo
28 NAFLD in T2DM: Prevalence in Hispanics and Role of Treatment Completed NCT01002547 Phase 4 pioglitazone-placebo;pioglitazone;pioglitazone-placebo;Vitamin E-placebo
29 Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus Completed NCT01761318 Phase 4 Liraglutide;Liraglutide - Placebo
30 PXR-aktivaation Vaikutus Maksan Rasvoittumiseen Completed NCT02329405 Phase 4 Rifampicin;Placebo
31 Impact of Short-term Fructose-enriched Diet on Serum Metabolome by Normal- and Over-weighed Women. Completed NCT03444233 Phase 4
32 Sepsis, Endothelial Function, and Lipids in Critically Ill Patients With Liver Failure (SELLIFA). Randomized Controlled Trial Comparing the Tolerance on Lipids and Safety of Isocaloric Parenteral Nutrition With Enteral Nutrition. Completed NCT00522730 Phase 4
33 Efficacy of Liraglutide vs. Sitagliptin vs. Insulin Glargine Per Day on Liver Fat When Combined With Metformin in T2DM Subjects With Non-alcoholic Fatty-liver Disease Completed NCT02147925 Phase 4 Liraglutide combined with metformin;Insulin glargine combined with metformin;Sitagliptin combined with metformin
34 Adding Liraglutide to High Dose Insulin: Breaking the Cycle Completed NCT01505673 Phase 4 Liraglutide;Saline
35 The Comparison of Effect Between Salsalate and Placebo in Osteoarthritis With Nonalcoholic Fatty Liver Disease: Investigator Initiated Randomized Placebo-controlled Double-blind, Pilot Study Completed NCT03222206 Phase 4 Salsalate
36 Effects of Metformin on Body Weight, Composition and Metabolic Derangements in Obese Children. A Randomized Clinical Trial Completed NCT02274948 Phase 4 Metformin;Placebo
37 The Effect of Vitamin D Supplementation on the Glycemic Control and Non-alcoholic Fatty Liver Disease in Type 2 Diabetes Completed NCT01854463 Phase 4 Vitamin D3;placebo
38 Use of Vitamin D in Treatment of Non-Alcoholic Fatty Liver Disease Detected by Transient Elastography Completed NCT04038853 Phase 4 1,25-Dihydroxyvitamin D;Placebo
39 Comparison of Efficacy of Liraglutide, Metformin and Gliclazide MR on Hepatic Lipid Content in Patients With Type 2 Diabetes (T2DM) and Non-alcoholic Fatty Liver (NAFLD) Completed NCT03068065 Phase 4 Liraglutide;Metformin;Gliclazide
40 A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD Completed NCT02285205 Phase 4 Oral administration of Lobeglitazone
41 Effect of Exenatide Treatment on Myocardial Fat Content, Left Ventricular Function, and Vascular Inflammation in Patients With Type 2 Diabetes Mellitus Completed NCT01951651 Phase 4 Exenatide;Glipizide
42 Pilot Phase IV, Multicenter, Randomized, Open-label and Controlled Study to Assess the Evolution of Peripheral Body Fat Distribution After Switching From Zidovudine Containing Backbone to Truvada in HIV-1-infected Patients on HAART (RECOMB Study). Completed NCT00324649 Phase 4 Truvada;Zidovudine/lamivudine
43 MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism in Patients With Prostate Cancer: Orchiectomy vs. Triptorelin Completed NCT02102646 Phase 4 Triptorelin
44 A Prospective, Randomized, Multicentre, Comparative and Open-label Study on Hepatotoxicity of ARIMIDEX Compared With Tamoxifen in Adjuvant Therapy in Postmenopausal Women With Hormone Receptor+ Early Breast Cancer Completed NCT00537771 Phase 4 Anastrozole;Tamoxifen
45 Effects of Empagliflozin on Liver Fat Content, Energy Metabolism and Body Composition in Patients With Type 2 Diabetes Completed NCT02637973 Phase 4 Empagliflozin;Placebo
46 Effect of Exenatide Treatment on Hepatic Fat Content and Plasma Adipocytokine Levels in Patients With Type 2 Diabetes Mellitus Completed NCT01432405 Phase 4 Exenatide;Pioglitazone
47 Study on Effects of Testosterone Replacement Therapy in Hypogonadal Type 2 Completed NCT03792321 Phase 4 Testosterone Undecanoate;Placebo
48 Anti-fatigue Effect of Korean Red Ginseng in Patients With Non-alcoholic Hepatitis Completed NCT02331589 Phase 4 KRG (Korea Red ginseng);Placebo (for KRG)
49 Cupping Therapy and SERKANGABIN Versus Conventional Treatment of Migraine Headache: a Randomized Controlled Trial Completed NCT01476930 Phase 4 conventional migraine drug treatment
50 Pilot Evaluation of the Influence of ABT450r, Ombitasvir, Dasabuvir +/- Ribavirin HCV Therapy on Insulin Resistance and Lipid Profile Completed NCT02734173 Phase 4 ABT450r-ABT267-ABT333 +/- Ribavirin

Search NIH Clinical Center for Fatty Liver Disease, Nonalcoholic 1

Genetic Tests for Fatty Liver Disease, Nonalcoholic 1

Genetic tests related to Fatty Liver Disease, Nonalcoholic 1:

# Genetic test Affiliating Genes
1 Fatty Liver Disease, Nonalcoholic 1 29
2 Hepatic Steatosis 29

Anatomical Context for Fatty Liver Disease, Nonalcoholic 1

MalaCards organs/tissues related to Fatty Liver Disease, Nonalcoholic 1:

41
Liver, Testes, Adipocyte, Heart, Endothelial, Kidney, Ovary

Publications for Fatty Liver Disease, Nonalcoholic 1

Articles related to Fatty Liver Disease, Nonalcoholic 1:

(show top 50) (show all 8786)
# Title Authors PMID Year
1
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. 38 8
22297845 2012
2
Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. 38 8
15565570 2004
3
NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis. 8
26934227 2016
4
Human fatty liver disease: old questions and new insights. 8
21700865 2011
5
Variant in PNPLA3 is associated with alcoholic liver disease. 8
19946271 2010
6
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. 8
18820647 2008
7
Ethnic differences in the prevalence of cryptogenic cirrhosis. 8
15046220 2004
8
Novel substituted heteroaromatic compounds as inhibitors of stearoyl-CoA desaturase. 9 38
20205608 2010
9
Plasma bilirubin and gamma-glutamyltransferase activity are inversely related in dyslipidemic patients with metabolic syndrome: relevance to oxidative stress. 9 38
20129611 2010
10
Stearoyl-coenzyme A desaturase 1 inhibition and the metabolic syndrome: considerations for future drug discovery. 9 38
20216310 2010
11
Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway. 9 38
20225248 2010
12
Reversal of mouse Acyl-CoA oxidase 1 (ACOX1) null phenotype by human ACOX1b isoform [corrected]. 9 38
20195242 2010
13
Hepatitis C and hepatic steatosis. 9 38
20139103 2010
14
A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis. 9 38
20070391 2010
15
Preliminary report: hepatic fat and inflammation in type 2 diabetes mellitus. 9 38
19850309 2010
16
Endoplasmic reticulum stress involved in the course of lipogenesis in fatty acids-induced hepatic steatosis. 9 38
19929925 2010
17
Hepatic steatosis in young lean insulin resistant women with polycystic ovary syndrome. 9 38
19171337 2010
18
Hepatic steatosis in hepatitis C is a storage disease due to HCV interaction with microsomal triglyceride transfer protein (MTP). 9 38
20178560 2010
19
Kupffer cells promote hepatic steatosis via interleukin-1beta-dependent suppression of peroxisome proliferator-activated receptor alpha activity. 9 38
20054868 2010
20
Interaction of adipokines and hepatitis B virus on histological liver injury in the Chinese. 9 38
19809411 2010
21
Animal models for hepatitis C and related liver disease. 9 38
20156300 2010
22
Hormonal regulation of acetyl-CoA carboxylase isoenzyme gene transcription. 9 38
20139635 2010
23
The relationship between serum adiponectin and steatosis in patients with chronic hepatitis C genotype-4. 9 38
20476641 2010
24
The increase in plasma PAI-1 associated with insulin resistance may be mediated by the presence of hepatic steatosis. 9 38
19656511 2010
25
Hepatic steatosis in a school population of overweight and obese adolescents. 9 38
20151095 2010
26
"Blinding" of AMP-dependent kinase by methylglyoxal: a mechanism that allows perpetuation of hepatic insulin resistance? 9 38
19643547 2009
27
Hepatic steatosis in overweight/obese females: new screening method for those at risk. 9 38
19960566 2009
28
Serum concentrations of human angiopoietin-like protein 3 in patients with nonalcoholic fatty liver disease: association with insulin resistance. 9 38
19474742 2009
29
Abnormal liver function test results are related to metabolic syndrome and BMI in Taiwanese adults without chronic hepatitis B or C. 9 38
19752878 2009
30
Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels. 9 38
19670414 2009
31
Long-term baicalin administration ameliorates metabolic disorders and hepatic steatosis in rats given a high-fat diet. 9 38
19890358 2009
32
Therapeutic potential of dithiolethiones for hepatic diseases. 9 38
19563826 2009
33
Stearoyl-CoA desaturase inhibitors: update on patented compounds. 9 38
19691439 2009
34
Genetic differences in oxidative stress and inflammatory responses to diet-induced obesity do not alter liver fibrosis in mice. 9 38
19490416 2009
35
Adipokine serum levels are related to liver histology in severely obese patients undergoing bariatric surgery. 9 38
19693638 2009
36
Azacycloalkane derivatives as inhibitors of delta-9 stearoyl-coenzyme A desaturase. 9 38
19473107 2009
37
A novel pregnane X receptor and S14-mediated lipogenic pathway in human hepatocyte. 9 38
19437491 2009
38
The emerging role of the endocannabinoid system in cardiovascular disease. 9 38
19357846 2009
39
Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease. 9 38
19475694 2009
40
Microarray analysis of hepatic gene expression identifies new genes involved in steatotic liver. 9 38
19258494 2009
41
Exogenous thioredoxin prevents ethanol-induced oxidative damage and apoptosis in mouse liver. 9 38
19205032 2009
42
Westernized-like-diet-fed rats: effect on glucose homeostasis, lipid profile, and adipocyte hormones and their modulation by rosiglitazone and glimepiride. 9 38
18407527 2009
43
Serum levels of adipokines in patients with chronic HCV infection: relationship with steatosis and fibrosis. 9 38
19608019 2009
44
Microsomal triglyceride transfer protein polymorphism (-493G/T) is associated with hepatic steatosis in patients with chronic hepatitis C. 9 38
19018985 2009
45
Young adult obese subjects with and without insulin resistance: what is the role of chronic inflammation and how to weigh it non-invasively? 9 38
19291292 2009
46
Effect of body weight and lifestyle changes on long-term course of nonalcoholic fatty liver disease in Koreans. 9 38
19214024 2009
47
Prolonged saturated fat-induced, glucose-dependent insulinotropic polypeptide elevation is associated with adipokine imbalance and liver injury in nonalcoholic steatohepatitis: dysregulated enteroadipocyte axis as a novel feature of fatty liver. 9 38
19141695 2009
48
Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. 9 38
19164855 2009
49
Ectopic fat deposition and the metabolic syndrome in obese children and adolescents. 9 38
19153496 2009
50
Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. 9 38
19053049 2009

Variations for Fatty Liver Disease, Nonalcoholic 1

ClinVar genetic disease variations for Fatty Liver Disease, Nonalcoholic 1:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 PRMT7 NM_019023.4(PRMT7): c.1713C> A (p.Cys571Ter) single nucleotide variant Pathogenic rs1251713297 16:68389688-68389688 16:68355785-68355785
2 PRMT7 NM_019023.4(PRMT7): c.322G> T (p.Glu108Ter) single nucleotide variant Pathogenic/Likely pathogenic rs1014959895 16:68363008-68363008 16:68329105-68329105
3 OPA1 NM_015560.2(OPA1): c.113_130del (p.Arg38_Ser43del) deletion Conflicting interpretations of pathogenicity rs863224140 3:193332592-193332609 3:193614803-193614820
4 PNPLA3 NM_025225.3(PNPLA3): c.64del (p.His22fs) deletion Uncertain significance 22:44319853-44319854 22:43923975-43923975
5 PNPLA3 NM_025225.3(PNPLA3): c.283C> T (p.Arg95Ter) single nucleotide variant Uncertain significance 22:44322910-44322910 22:43927030-43927030
6 PNPLA3 NM_025225.3(PNPLA3): c.1186C> T (p.Arg396Ter) single nucleotide variant Uncertain significance 22:44340644-44340644 22:43944764-43944764
7 MT-TL1 NC_012920.1: m.3275C> T single nucleotide variant Uncertain significance rs1057516057 MT:3275-3275 MT:3275-3275

Expression for Fatty Liver Disease, Nonalcoholic 1

Search GEO for disease gene expression data for Fatty Liver Disease, Nonalcoholic 1.

Pathways for Fatty Liver Disease, Nonalcoholic 1

Pathways related to Fatty Liver Disease, Nonalcoholic 1 according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.82 SREBF1 PPARA PNPLA3 MTTP INS HADHA
2
Show member pathways
12.53 RETN LEP INS ADIPOQ
3
Show member pathways
12.41 SREBF1 PPARA LEP HADHA FABP1 ADIPOQ
4 12.2 SREBF1 INS FABP1 ADIPOQ
5
Show member pathways
12.08 SREBF1 LEP INS ADIPOQ
7
Show member pathways
11.65 SREBF1 PPARA INS
8 11.38 PPARA FABP1 ADIPOQ
9 11.29 SREBF1 RETN PPARA PNPLA3 LEP INS
10 11.27 PPARA LEP ADIPOQ
11 10.95 PPARA FABP1
12 10.91 LEP ADIPOQ
13 10.84 LEP ADIPOQ
14 10.76 SREBF1 PPARA
15 10.66 INS GPT

GO Terms for Fatty Liver Disease, Nonalcoholic 1

Biological processes related to Fatty Liver Disease, Nonalcoholic 1 according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 response to hypoxia GO:0001666 9.76 PPARA LEP ADIPOQ
2 glucose homeostasis GO:0042593 9.69 LEP INS ADIPOQ
3 lipid metabolic process GO:0006629 9.63 SREBF1 PPARA PNPLA3 MTTP LEP HADHA
4 positive regulation of glucose import GO:0046326 9.6 INS ADIPOQ
5 negative regulation of blood pressure GO:0045776 9.59 PPARA ADIPOQ
6 triglyceride catabolic process GO:0019433 9.58 PNPLA3 FABP1
7 response to lipid GO:0033993 9.57 SREBF1 PPARA
8 lipoprotein metabolic process GO:0042157 9.56 PPARA MTTP
9 positive regulation of insulin receptor signaling pathway GO:0046628 9.55 LEP INS
10 positive regulation of cellular protein metabolic process GO:0032270 9.54 INS ADIPOQ
11 negative regulation of gluconeogenesis GO:0045721 9.52 INS ADIPOQ
12 glucose metabolic process GO:0006006 9.5 LEP INS ADIPOQ
13 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.49 PPARA ADIPOQ
14 intestinal absorption GO:0050892 9.48 LEP FABP1
15 positive regulation of fatty acid beta-oxidation GO:0032000 9.46 PPARA FABP1
16 negative regulation of appetite GO:0032099 9.43 PPARA LEP
17 fatty acid beta-oxidation GO:0006635 9.43 LEP HADHA ADIPOQ
18 negative regulation of feeding behavior GO:2000252 9.37 RETN INS
19 circadian rhythm GO:0007623 9.26 SREBF1 MTTP LEP ADIPOQ
20 regulation of fatty acid metabolic process GO:0019217 9.1 SREBF1
21 response to insulin GO:0032868 8.92 RETN PPARA LEP HADHA

Molecular functions related to Fatty Liver Disease, Nonalcoholic 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 fatty acid binding GO:0005504 8.96 PPARA FABP1
2 hormone activity GO:0005179 8.92 RETN LEP INS ADIPOQ

Sources for Fatty Liver Disease, Nonalcoholic 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....